Literature DB >> 3236176

Early experience with open fetal surgery for congenital hydronephrosis.

T M Crombleholme1, M R Harrison, J C Langer, M T Longaker, R L Anderson, N S Slotnick, R A Filly, P W Callen, R B Goldstein, M S Golbus.   

Abstract

The fetus with severe bilateral hydronephrosis and associated oligohydramnios in the second trimester is doomed at birth by ongoing pulmonary and renal damage. Since decompression with percutaneously placed catheters anesthetic, surgical, and tocolytic techniques for open fetal anesthetic, surgical, and tocolytic techniques for open fetal urinary tract decompression in animals, and have now applied those techniques to a small group of five patients. One had bilateral ureterostomies and the subsequent four had marsupialization of the bladder. All pregnancies proceeded to cesarean delivery at 32 to 35 weeks' gestation. There was no long-term maternal morbidity, and two mothers have since experienced normal pregnancies. Three fetuses had return of normal amniotic fluid dynamics, and all three had adequate pulmonary function at birth, suggesting that fatal pulmonary hypoplasia associated with early severe oligohydramnios had been reversed. Two neonates died at birth with pulmonary hypoplasia. One had no amniotic fluid even after decompression, and the other had some amniotic fluid after decompression but a tiny chest cavity due to the long period of severe oligohydramnios before decompression. Of the three surviving infants, one had normal renal function when she died of unrelated causes at 9 months of age. One has normal renal function at 23 months and the third had failing renal function at 2 1/2 years and has grown and developed normally, but will require renal transplantation. We have now developed selection criteria that would exclude from treatment the two fetuses who died of pulmonary hypoplasia and the one who developed renal failure.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1988        PMID: 3236176     DOI: 10.1016/s0022-3468(88)80325-7

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  19 in total

1.  Best of the AUA Annual Meeting: Highlights From the 2011 American Urological Association Meeting, May 14-19, 2011, Washington, DC.

Authors:  Michael K Brawer; Stacy Loeb; Alan W Partin; Jayabalan Nirmal; Michael B Chancellor; J Curtis Nickel; Jacob Rajfer; Ellen Shapiro; Claus G Roehrborn
Journal:  Rev Urol       Date:  2011

2.  Studies in fetal wound healing. V. A prolonged presence of hyaluronic acid characterizes fetal wound fluid.

Authors:  M T Longaker; E S Chiu; N S Adzick; M Stern; M R Harrison; R Stern
Journal:  Ann Surg       Date:  1991-04       Impact factor: 12.969

Review 3.  Management of fetal hydronephrosis.

Authors:  Jenny Yiee; Duncan Wilcox
Journal:  Pediatr Nephrol       Date:  2007-08-02       Impact factor: 3.714

Review 4.  On the horizon: neonatal lung transplantation.

Authors:  N S Adzick
Journal:  Arch Dis Child       Date:  1992-04       Impact factor: 3.791

5.  Scarless fetal healing. Therapeutic implications.

Authors:  N S Adzick; M T Longaker
Journal:  Ann Surg       Date:  1992-01       Impact factor: 12.969

6.  Cellular inflammation of fetal excisional wounds: effects of amniotic fluid exclusion.

Authors:  M J Morykwas; M S Ledbetter; J A Ditesheim; W L White; A D Vander Ark; L C Argenta
Journal:  Inflammation       Date:  1991-06       Impact factor: 4.092

7.  Fetal obstructive uropathy.

Authors:  M T Longaker; N S Adzick; M R Harrison
Journal:  BMJ       Date:  1989-07-29

8.  Fetal surgery at the crossroads.

Authors:  J Hutson
Journal:  Indian J Pediatr       Date:  1989 Sep-Oct       Impact factor: 1.967

Review 9.  In utero intervention for urologic diseases.

Authors:  Douglass B Clayton; John W Brock
Journal:  Nat Rev Urol       Date:  2012-02-21       Impact factor: 14.432

Review 10.  Current State of Fetal Intervention for Lower Urinary Tract Obstruction.

Authors:  Douglass B Clayton; John W Brock
Journal:  Curr Urol Rep       Date:  2018-02-22       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.